Department Of Neurooncology
Investigator
Aya Haggiagi, MD
Phone
212-305-2460
Email
amh2237@cumc.columbia.edu

Aya Haggiagi, MD is an assistant professor of neurology at CUIMC, in the Division of Neuro-Oncology. Dr. Haggiagi is board certified in Neurology and Neuro-Oncology. She graduated with highest honors from the University of Al-Fateh School of Medicine in Tripoli, Libya. She subsequently completed a postdoctoral research fellowship in the Department of Pathology and Cell Biology at Columbia, under the mentorship of Dr. Michael Shelanski, where her research focused on biochemical and genetic changes in neurofibrillary tangle predominant dementia. Dr. Haggiagi then pursued her medicine internship training at Westchester Medical Center, followed by neurology residency at NewYork-Presbyterian/Columbia University Irving Medical Center. After residency, she completed a two-year fellowship in Neuro-Oncology at Memorial Sloan Kettering Cancer Center.

Dr. Haggiagi was an attending physician and an investigator at Memorial Sloan Kettering Cancer Center prior to returning to NYP/CUIMC. She is the recipient of the Society for Neuro-Oncology 2017 Best Abstract Award. Her research interests include the development of clinical trials, precision medicine, and neurologic complications of immunotherapy.


Clinical Studies Managed By This Investigator:
Condition Study Title
Brain Tumors [ CLOSED ] ANG1005 in Leptomeningeal Disease From Breast Cancer (ANGLeD)
Brain Tumors [ CLOSED ] Nivolumab and Multi-fraction Stereotactic Radiosurgery (Non-Surgical Radiation Therapy) in Treating Participants With Meningioma
Brain Cancer Study of ONC201 After Radiation in Patients with Glioma
Brain Tumors Study of ONC201 After Radiation in Patients with Glioma
Brain Cancer Study of PF-07799544 in Patients with Solid Brain Tumors
Brain Tumors Study of PF-07799544 in Patients with Solid Brain Tumors
Brain Cancer Study of Radiosurgery & Nivolumab Alone or in Combination with Ipilimumab in Patients with Meningioma
Brain Tumors Study of Radiosurgery & Nivolumab Alone or in Combination with Ipilimumab in Patients with Meningioma